2025 – an incredible journey for IVD TRIALS

This has truly been an exceptional year with several important milestones:

Medical professionals celebrating a successful collaboration in a clinical setting, emphasizing IVD trial approvals and advancements in health science.
  • First of all, the establishment of IVD TRIALS as an independent company: from a department within BIOMEX GmbH, we officially became our own entity on Jan 1, 2025 – a significant and exciting step for our entire study team.
  • Launching and coordinating multiple new study types, including HbA1c rapid tests or the first validations Class B and C products under EU IVDR for our customers
  • Introducing new staff, e.g. for project management and data management (EDC), as well as corresponding IT tools

We are deeply grateful

for a year filled with growth, teamwork, and important achievements - and we look forward to 2026, ready for new studies, new challenges, and continued growth as an independent organization.

Similar Posts